The FDA has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in children and adults

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia